fr   en
Agreements
Select a partner :
Type of agreement :





Select a compound/Disease :
Choose date:
[<<]      «      55   |   56   |   57   |   58   |   59   |   60   |   61   |   62   |   63   |   64   |   65      »      [65]
Date Partners Compound / Disease area / Development phase Type of agreement Nature / Financial terms
2007-01-15 Fovea Pharmaceuticals (France)
Novartis (Switzerland)
RdCVF / pigmentary retinitis, degenerative retinal diseases commercialization/ distribution
development
See details
2007-01-14 Crucell (The Netherlands)/DSM Biologics (The Netherlands)/Abgenomics (Taiwan)
 
PER.C6® human line cell / cancer, immune diseases licensing
See details
2007-01-12 BioInvent (Sweden)
Genentech (USA)
BI-204 (monoclonal antibody targeting a mediator of vascular inflammation that is believed to lead to the formation of unstable plaque in the vessel wall) / cardiovascular diseases R&D
commercialization/ distribution
See details
2007-01-11 Kinaxo Biotechnologies (Germany)
J&J (USA)
Kinator® technology
(This technology uses immobilized small molecule inhibitors to detect their protein binding partners in biological samples)
other
See details
2007-01-09 Stallergènes (France)/Paladin (Canada)
 
Oralair® range:
- Oralair®Graminees against hay fever, Oralair®Acariens for the treatment of allergic rhinitis in patients sensitized to mites
- Oralair®Bouleau for the treatment of the allergic rhinitis in patients sensitized to birch pollen / Allergies
commercialization/ distribution
development
marketing/ promotion
See details
2007-01-09 Huya Bioscience International (China)
Organon (The Netherlands)
  / undisclosed therapeutic areas R&D
See details
2007-01-08 Ablynx (Belgium)
Boehringer Ingelheim (Germany)
Nanobodies® / Alzheimer's disease R&D
See details
2007-01-05 Crucell (The Netherlands)/DSM Biologics (The Netherlands)/Biotecnol (Portugal)
 
PER.C6® human line cell / cancer licensing
See details
2007-01-03 Exelixis (USA)/Genentech (USA)
 
XL518 (a MEK/MAP kinase inhibitor) / tumours development
See details
2006-12-27 Crucell (The Netherlands)
Merck&Co (USA)
PER.C6® technology /   licensing
See details
2006-12-20 Morphosys (Germany)
Pfizer (USA)
therapeutic antibodies /   R&D
See details
2006-12-19 Genmab (Denmark)
GSK (UK)
Humax-CD20 (ofatumumab - Arzerra®) / chronic lymphoid leukaemia, non-Hodgkin's lymphoma, rheumatoid arthritis commercialization/ distribution
development
See details
2006-12-13 Graffinity (Germany)
Boehringer Ingelheim (Germany)
  R&D
other
See details
2006-12-11 Pharminox (UK)
Schering-Plough (USA)
anticancer drugs / cancer R&D
See details
2006-12-11 Galapagos (Belgium)
 
treatments for amyotrophic lateral sclerosis / amyotrophic lateral sclerosis R&D
See details
[<<]      «      55   |   56   |   57   |   58   |   59   |   60   |   61   |   62   |   63   |   64   |   65      »      [65]